PMC10242066_01
Changes in the patient's intestinal mucosa. (A) In January 2019, prior to the application of infliximab, colonoscopy showed multiple ulcers at the end of the ileum; (B) In August 2019, colonoscopy revealed a large bulging lesion in the cecum and ascending colon; (C) In January 2021, colonoscopy again showed multiple large ulcers in the ileum and anastomosis; (D) In September 2022, one year after vedolizumab treatment colonoscopy showed complete healing of the ileal ulcers.
fimmu-14-1205046-g001.jpg
PMC10242066_01_fimmu-14-1205046-g001.jpg
f1
Colonoscopy showed multiple ulcers in the distal ileum and large protuberant lesions in the cecum and ascending colon ( Figures 1A, B ). Colonoscopy showed multiple large ulcers in the ileum and anastomotic orifice ( Figure 1C ). On September 30, 2022, a colonoscopy showed a completely healed ileal ulcer with a smooth mucosal surface and well-dilated intestine ( Figure 1D ).
Pathology images from the right radical hemicolectomy. H&E staining revealed an irregular glandular arrangement of the mucosal epithelium with a large amount of mucus visible in the background and infiltrative growth.
fimmu-14-1205046-g002.jpg
PMC10242066_01_fimmu-14-1205046-g002.jpg
f2
Post-operative pathology confirmed the mucinous tumor ( Figure 2 ).
Efficacy of vedolizumab in the treatment of intestinal Behcet's Disease. (A) Changes of white blood cell (WBC); (B) Changes of C-reactive protein (CRP); (B) Changes in erythrocyte sedimentation rate (ESR); (C) Changes in indices of disease activity in intestinal Behcet's Disease (DAIBD).
fimmu-14-1205046-g003.jpg
PMC10242066_01_fimmu-14-1205046-g003.jpg
f3
As shown in  Figures 3A-C , although all systemic inflammatory indices showed repeat increases, such as WBC, CRP, and ESR, these might be caused by the presence of inflammation outside of the gastrointestinal (GI) tract. As only focused on the GI tract ( Figure 3D ), the DAIBD showed the significant efficacy of VDZ on intestinal BD.